CTLA-4-Ig that binds to CD80 and CD86 and has an inhibitory effect on the CD80/CD86–CD28 costimulation pathway is clinically effective in treating rheumatoid arthritis [37], and has also been shown to protect against experimental atherosclerosis [38]. This evidence concerns the gene CD86 and rheumatoid arthritis.